Clinical Trial Update: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Prexasertib in combination with chemotherapy and radiation for head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Prexasertib (prexasertib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Head and Neck Neoplasms | Phase 1 | Status: COMPLETED